DoNews6月25日消息,近日,多家媒体报道称,传奇生物(NASDAQ: LEGN)已取消中国的销售和市场团队,仅保留研发部门。这一消息随后被多名业内人士证实。“看这个举措,大概率不在国内做商业化,GMP(药品生产质量管理规范)团队都离开了。”一位业内人士透露。一名投资人进一步补充:“他们目前在中国的业务,主要保留了研发部门。其他团队都遭到了不同程度的裁减。”传奇生物此次裁撤中国销售团队的行动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.